T 02106

Drug Profile

T 02106

Alternative Names: T 2106

Latest Information Update: 20 Oct 1995

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antigenics
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 20 Oct 1995 Hoechst is no longer a licensee.
  • 15 Aug 1995 Discontinued-Preclinical for Herpes simplex virus infections in USA (Unknown route)
  • 19 Jun 1995 This profile is new.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top